VIIV HEALTHCARE PTY LTD

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

EuroSIDA As An External Comparator To MOTIVATE Trials

Completed

Conditions: HIV
AIDS

Interventions: Other: maraviroc

First Posted Date: 2011-04-06

Last Posted Date: 2011-05-16

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 1181

Registration Number: NCT01329783

A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.

Phase 3

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: dolutegravir

First Posted Date: 2011-04-04

Last Posted Date: 2016-01-07

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 183

Registration Number: NCT01328041

Locations: 🇪🇸
GSK Investigational Site, Sevilla, Spain

A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B

Phase 4

Completed

Conditions: HIV Coinfection

Interventions: Drug: Placebo
Drug: Maraviroc

First Posted Date: 2011-04-01

Last Posted Date: 2017-12-06

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 138

Registration Number: NCT01327547

Locations: 🇺🇸
AIDS Research Alliance, Los Angeles, California, United States
🇺🇸
Georgia Regents Medical Center, Augusta, Georgia, United States
🇺🇸
Saint Michael's Medical Center, Newark, New Jersey, United States

and more 45 locations

Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Maraviroc
Drug: Fosamprenavir/ritonavir
Drug: Maraviroc + Fosamprenavir/ritonavir

First Posted Date: 2011-02-04

Last Posted Date: 2011-06-29

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 28

Registration Number: NCT01290211

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.

Phase 1

Withdrawn

Conditions: Infection, Human Immunodeficiency Virus I

Interventions: Drug: GSK1349572
Drug: GSK2248761

First Posted Date: 2011-01-25

Last Posted Date: 2014-12-24

Lead Sponsor: ViiV Healthcare

Registration Number: NCT01283100

Locations: 🇺🇸
GSK Investigational Site, Buffalo, New York, United States

Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia

Phase 4

Completed

Conditions: HIV

Interventions: Drug: HIV therapy

First Posted Date: 2011-01-12

Last Posted Date: 2014-03-03

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 98

Registration Number: NCT01275625

Locations: 🇷🇺
Moscow regional center on AIDS and infectious diseases prophylaxis and control, Moscow, Russian Federation
🇷🇺
Federal State Institution Republican clinical infectious hospital of Roszdrav, Saint-Petersburg, Russian Federation
🇷🇺
Regional Center on AIDS and Infectious Diseases Prophylaxis and Control, Nizhnij Novgorod, Russian Federation

and more 4 locations

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects

Phase 1

Withdrawn

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: 200mg [14C]- GSK2248761

First Posted Date: 2011-01-10

Last Posted Date: 2014-05-19

Lead Sponsor: ViiV Healthcare

Registration Number: NCT01273103

Locations: 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Phase 3

Completed

Conditions: Infection, Human Immunodeficiency Virus I

Interventions: Drug: Dolutegravir
Drug: Atripla
Drug: Abacavir/Lamivudine
Drug: Abacavir/Lamivudine Placebo
Drug: Atripla placebo
Drug: Dolutegravir placebo

First Posted Date: 2010-12-20

Last Posted Date: 2018-04-04

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 844

Registration Number: NCT01263015

Locations: 🇬🇧
GSK Investigational Site, Tooting, London, United Kingdom

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults

Phase 3

Completed

Conditions: HIV Infections
Infection, Human Immunodeficiency Virus

Interventions: Drug: GSK1349572
Drug: Raltegravir
Drug: Raltegravir Placebo
Drug: GSK1349572 Placebo

First Posted Date: 2010-11-01

Last Posted Date: 2022-03-15

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 724

Registration Number: NCT01231516

Locations: 🇬🇧
GSK Investigational Site, Tooting, London, United Kingdom

Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: GSK1349572
Drug: Rifampin
Drug: Rifabutin

First Posted Date: 2010-11-01

Last Posted Date: 2017-06-08

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 27

Registration Number: NCT01231542

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy